A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

(2021) Robert L. Gottlieb et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

(2021) Jeroen J. A. van Kampen et al.   Nature Communications

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2

(2021) Wendy P. Painter et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19

(2021) Maria Dolores Folgueira et al.   CLINICAL MICROBIOLOGY AND INFECTION

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

(2021) Angela Wahl et al.   NATURE

Antibody evasion by the P.1 strain of SARS-CoV-2

(2021) Wanwisa Dejnirattisai et al.   CELL

Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template

(2021) Calvin J. Gordon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model

(2021) Rana Abdelnabi et al.   JOURNAL OF INFECTIOUS DISEASES

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

(2021) Florian Kabinger et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Predicting infectious SARS-CoV-2 from diagnostic samples

(2020) Jared Bullard et al.   CLINICAL INFECTIOUS DISEASES

Clinical progression of patients with COVID-19 in Shanghai, China

(2020) Jun Chen et al.   JOURNAL OF INFECTION

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

(2020) Timothy P. Sheahan et al.   Science Translational Medicine

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020

(2020) Anika Singanayagam et al.   Eurosurveillance

Viral dynamics in mild and severe cases of COVID-19

(2020) Yang Liu et al.   LANCET INFECTIOUS DISEASES

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

(2020) Lakshmanane Premkumar et al.   Science Immunology

Author Correction: Virological assessment of hospitalized patients with COVID-2019

(2020) Roman Wölfel et al.   NATURE

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

(2020) David M. Weinreich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

(2020) Teresa Aydillo et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

(2020) Peter Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

(2020) Robert M. Cox et al.   Nature Microbiology

The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection

(2019) George R. Painter et al.   ANTIVIRAL RESEARCH

Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

(2019) Maria L. Agostini et al.   JOURNAL OF VIROLOGY